title: Effect of diet, enalapril, or losartan in post-diarrheal hemolytic uremic syndrome nephropathy.
abstract: Proteinuria is the main indicator of renal disease progression in many chronic conditions. There is currently little information available on the efficacy, safety, and individual tolerance of patients with post-diarrheal hemolytic uremic syndrome (D+ HUS) nephropathy to therapies involving diet, enalapril, or losartan. A multicenter, double-blind, randomized controlled trail was conducted to evaluate the effect of a normosodic-normoproteic diet (Phase I) and the effect of normosodic-normoproteic diet plus enalapril (0.18-0.27 mg/kg/day) or losartan (0.89-1.34 mg/kg/day) (Phase II) on children with D+ HUS, normal renal function, and persistent, mild (5.1-49.9 mg/kg/day) proteinuria. Dietary intervention reduced the mean protein intake from 3.4 to 2.2 mg/kg/day. Of 137 children, proteinuria normalized in 91 (66.4 %) within 23-45 days; the remaining 46 patients were randomized to diet plus placebo (group 1, n = 16), plus losartan (group 2, n = 16), or enalapril (group 3, n = 14). In groups 1, 2, and 3, proteinuria was reduced by 30.0, 82.0, and 66.3%, respectively, and normalized in six (37.5%), three (81.3%), and 11 (78.6%) patients, respectively (χ(2)= 8.9, p = 0.015). These results suggest that: (1) a normosodic-normoproteic diet can normalize proteinuria in the majority of children with D+ HUS with mild sequelae, (2) the addition of enalapril or losartan to such dietary restrictions of protein further reduces proteinuria, and (3) these therapeutic interventions are safe and well tolerated. Whether these short-term effects can be extended to the long-term remains to be demonstrated.
authors.affiliation: Hospital Garrahan, Buenos Aires, Argentina. mcaletti@garrahan.gov.ar
authors.forename: Maria Gracia
authors.initials: MG
authors.lastname: Caletti
authors.forename: Mabel
authors.initials: M
authors.lastname: Missoni
authors.forename: Clarisa
authors.initials: C
authors.lastname: Vezzani
authors.forename: María
authors.initials: M
authors.lastname: Grignoli
authors.forename: Juan Jose
authors.initials: JJ
authors.lastname: Piantanida
authors.forename: Horacio A
authors.initials: HA
authors.lastname: Repetto
authors.forename: Ramon
authors.initials: R
authors.lastname: Exeni
authors.forename: Stella Maris
authors.initials: SM
authors.lastname: Rasse
mesh_terms: D000328:Adult; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003967:Diarrhea / Q000150:complications; D004035:Diet Therapy / Q000379:methods*; D004311:Double-Blind Method; D004656:Enalapril / Q000627:therapeutic use*; D005260:Female; D006463:Hemolytic-Uremic Syndrome / Q000628:therapy*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000517:prevention & control; D019808:Losartan / Q000627:therapeutic use*; D008297:Male; D011507:Proteinuria / Q000628:therapy
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril; D019808:Losartan